McHardy et al. “Discovery of 4-Amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides As Selective, Orally Active Inhibitors of Protein Kinase B (Akt).” Journal of Medicinal Chemistry 53, no. 5 2010: 2239–2249. DOI: 10.1021/jm901788j.

McHardy et al. “Discovery of 4-Amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides As Selective, Orally Active Inhibitors of Protein Kinase B (Akt).” Journal of Medicinal Chemistry 53, no. 5 2010: 2239–2249. DOI: 10.1021/jm901788j.

Murray et al. “Fragment-Based Drug Discovery Applied to HSP90. Discovery of Two Lead Series with High Ligand Efficiency.” Journal of Medicinal Chemistry 53, no. 16 2010: 5942–5955. DOI: 10.1021/jm100059d.

Murray et al. “Fragment-Based Drug Discovery Applied to HSP90. Discovery of Two Lead Series with High Ligand Efficiency.” Journal of Medicinal Chemistry 53, no. 16 2010: 5942–5955. DOI: 10.1021/jm100059d.

Santo et al. “AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition.” Oncogene 29, no. 16 2010: 2325-2336. DOI: 10.1038/onc.2009.510.

Santo et al. “AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition.” Oncogene 29, no. 16 2010: 2325-2336. DOI: 10.1038/onc.2009.510.

Squires M. et al. “AT7519, a Cyclin-Dependent Kinase Inhibitor, Exerts Its Effects by Transcriptional Inhibition in Leukemia Cell Lines and Patient Samples.” Molecular Cancer Therapeutics 9, no. 4 2010: 920-928. DOI: 10.1158/1535-7163.MCT-09-1071.

Squires M. et al. “AT7519, a Cyclin-Dependent Kinase Inhibitor, Exerts Its Effects by Transcriptional Inhibition in Leukemia Cell Lines and Patient Samples.” Molecular Cancer Therapeutics 9, no. 4 2010: 920-928. DOI: 10.1158/1535-7163.MCT-09-1071.

Tanaka et al. “Activity of the multi-targeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL positive leukemic cells.” Blood 116, no. 12 2010: 2089-2095. DOI: 10.1182/blood-2009-03-211466.

Tanaka et al. “Activity of the multi-targeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL positive leukemic cells.” Blood 116, no. 12 2010: 2089-2095. DOI: 10.1182/blood-2009-03-211466.

Woodhead et al. “Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design.” Journal of Medicinal Chemistry 53, no. 16 2010: 5956–5969. DOI: 10.1021/jm100060b.

Woodhead et al. “Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design.” Journal of Medicinal Chemistry 53, no. 16 2010: 5956–5969. DOI: 10.1021/jm100060b.

Christopher W. Murray and David C. Rees. “The rise of fragment based drug discovery.” Nature Chemistry 1, no. 3 2009: 187-192. DOI: 10.1038/nchem.217.

Christopher W. Murray and David C. Rees. “The rise of fragment based drug discovery.” Nature Chemistry 1, no. 3 2009: 187-192. DOI: 10.1038/nchem.217.

Curry J. et al. “Aurora kinase inhibition in mitosis: Strategies for optimising the use of aurora kinase inhibitors such as AT9283.” Cell Cycle 8, no. 12 2009: 1-9. DOI: 10.4161/cc.8.12.8741.

Curry J. et al. “Aurora kinase inhibition in mitosis: Strategies for optimising the use of aurora kinase inhibitors such as AT9283.” Cell Cycle 8, no. 12 2009: 1-9. DOI: 10.4161/cc.8.12.8741.

Davies et al. “Fragment-Based Discovery of Inhibitors of Protein Kinase B.” Current Topics in Medicinal Chemistry 9, no. 18 2009: 1705-1717.

Davies et al. “Fragment-Based Discovery of Inhibitors of Protein Kinase B.” Current Topics in Medicinal Chemistry 9, no. 18 2009: 1705-1717.

Day et al. “Crystal structure of human CDK4 in complex with a D-type cyclin.” Proceedings of the National Academy of Sciences 106, no. 11 2009: 4166-4170. DOI: 10.1073/pnas.0809645106.

Day et al. “Crystal structure of human CDK4 in complex with a D-type cyclin.” Proceedings of the National Academy of Sciences 106, no. 11 2009: 4166-4170. DOI: 10.1073/pnas.0809645106.